Organon & Co. Investors: Please contact the Portnoy Law Firm to recover your losses. July 22, 2025 Deadline to file Lead Plaintiff Motion

June 30, 2025 02:00 PM PDT | By EODHD

Google News:

Organon & Co. Investors: Please contact the Portnoy Law Firm to recover your losses. July 22, 2025 Deadline to file Lead Plaintiff Motion — Image source: Kalkine Media

Recent News

Block3 Unveils Prompt-To-Game AI Engine As Presale Launches

Copper price surge signals strain, but no acute shortage yet

Long XAU/AUD: strong rebound from 5000 support zone and oversold regio...

Blizzard the Avalanche Fund Leads Datagram’s $4M Pre-Seed Round to Bec...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 30, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Organon & Co. ("Organon" or the "Company") (NYSE:OGN) investors of a class action representing investors that bought securities between October 31, 2024 to April 30, 2025, inclusive (the "Class Period"). Organon investors have until July 22, 2025to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case.

The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses. CASE ALLEGATIONS: Organon is a healthcare company that develops and delivers prescription therapies and medical devices. According to the class action lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose material facts, including that: (i) Organon concealed critical information regarding its capital allocation strategy—particularly its plans for the quarterly dividend payout; (ii) despite public statements positioning the dividend as the company’s “number one priority,” Organon had adopted a debt reduction strategy that conflicted with maintaining the dividend; and (iii) following its acquisition of Dermavant Sciences Ltd., Organon intended to shift capital priorities toward debt reduction, leading to a substantial dividend cut. The Complaint further alleges that on May 1, 2025, Organon released its Q1 2025 financial results and announced a sharp reduction in its quarterly dividend—from $0.28 to $0.02 per share. On this news, Organon’s stock declined more than 27%, according to the Complaint.

Please visit our website to review more information and submit your transaction information. The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq. Admitted CA and NY Bar [email protected] 310-692-8883 www.portnoylaw.com Attorney Advertising

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.